Viewing data from:

SUBVENITE

NDA

LAMOTRIGINE | N218879 | OWP PHARMACEUTICALS INC

1 strength4 unique patents0 unique exclusivities

Patent Timeline

4 unique patents by expiration date

Active (4)Today

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

2037

2038

2039

2040

2041

Today

May. 29, 2040

May. 29, 2040

May. 29, 2040

May. 29, 2040

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

143 trials from ClinicalTrials.gov — 2 recruiting, 120 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)NCT06929273	Phase 3	Recruiting	Bristol-Myers Squibb	450	2025-07-18 → 2028-06-13
Ketogenic Diet for New-Onset Absence Epilepsy NCT04274179	Phase 3	Recruiting	Johns Hopkins University	40	2020-08-10 → 2028-05-01
Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain NCT03419949	—	AVAILABLE	Assiut University	—	—
Interaction Between Paracetamol and Lamotrigine: A Clinical Interaction Study NCT02303106	Phase 4	Completed	Per Damkier	12	2014-11 → 2015-04
Bipolar Disorder Study for Men and Women NCT00056277	Phase 3	Completed	GlaxoSmithKline	150	2003-02-27 → 2005-12-14
Lamotrigine Monotherapy in Pediatric Bipolar Disorder NCT00176228	Phase 2	Completed	University of Illinois at Chicago	48	2004-02 → 2008-01
A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures NCT00292461	Phase 3	Completed	Eisai Inc.	64	2006-03 → 2009-09
The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy NCT00807989	Phase 4	Completed	Yonsei University	207	2008-03 → 2012-05
Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fed Condition NCT01131975	Phase 1	Completed	Dr. Reddy's Laboratories Limited	26	2003-01 → 2003-03
Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer NCT00068445	Phase 3	Completed	Alliance for Clinical Trials in Oncology	131	2004-02 → 2013-11

Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 1 NDC

Highest NADAC/Unit

$2.87

per ml

Lowest NADAC/Unit

$2.87

per ml

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
69102041801SUBVENITE 10 MG/ML SUSPENSION	$2.87	ML	Brand	—	2026-08-19

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 1 NDC (1 FSS)

Lowest Price

$549.95

Highest Price

$549.95

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
69102-0418-01SUBVENITE 10MG/ML SUSP,ORAL	$549.95	FSS	OWP PHARMACEUTICALS, INC.	07/31/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Subvenite (2024)

Total Spending

$12K

Total Claims

821

Beneficiaries

220

Avg Cost/Unit

$0.17

Spending Trend

$21K(2019)→$32K(2020)→$20K(2021)→$26K(2022)→$22K(2023)→$12K(2024)

YoY Change:-31.0%

5yr CAGR:-4.5%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain25 active DMFs9 inactive

23 active API suppliers hold Drug Master Files for this ingredient.

TAPI NL BVLAMOTRIGINE

DMF 159242002

JUBILANT BIOSYS LTDLAMOTRIGINE USP

DMF 161422002

COHANCE LIFESCIENCES LTDLAMOTRIGINE USP

DMF 162592002

DR REDDYS LABORATORIES LTDLAMOTRIGINE

DMF 164802003

MEDICHEM SALAMOTRIGINE

DMF 172312004

MATRIX PHARMACORP PRIVATE LTDLAMOTRIGINE USP

DMF 177402004

ZYDUS LIFESCIENCES LTDLAMOTRIGINE USP

DMF 180902005

CIPLA LTDLAMOTRIGINE USP

DMF 184212005

ALEMBIC PHARMACEUTICALS LTDLAMOTRIGINE USP

DMF 187322005

TARO PHARMACEUTICAL INDUSTRIES LTDLAMOTRIGINE USP

DMF 189602005

ZHEJIANG SUPOR PHARMACEUTICALS CO LTDLAMOTRIGINE, USP

DMF 195412006

LUPIN LTDLAMOTRIGINE USP (MICRONISED)

DMF 198922006

APITORIA PHARMA PRIVATE LTDLAMOTRIGINE USP (NON-STERILE DRUG SUBSTANCE)

DMF 199082006

TORRENT PHARMACEUTICALS LTDLAMOTRIGINE USP

DMF 202892007

ZAKLADY FARMACEUTYCZNE POLPHARMA SALAMOTRIGINE

DMF 205482007

UNICHEM LABORATORIES LTDLAMOTRIGINE USP API

DMF 208352007

UNIMARK REMEDIES LTDLAMOTRIGINE USP

DMF 228132009

COHANCE LIFESCIENCES LTDLAMOTRIGINE USP

DMF 232512009

ZHEJIANG HUAHAI PHARMACEUTICAL CO LTDLAMOTRIGINE USP

DMF 232622009

SYNTHEXIM CALAIRE CHIMIELAMOTRIGINE DRUG SUBSTANCE

DMF 237402010

CTX LIFE SCIENCES PVT LTDLAMOTRIGINE USP

DMF 249582011

IOL CHEMICALS AND PHARMACEUTICALS LTDLAMOTRIGINE

DMF 266272012

SYN-TECH CHEM AND PHARM CO LTDLAMOTRIGINE USP

DMF 302702016

SMS PHARMACEUTICALS LTDLAMOTRIGINE USP

DMF 342902019

IOL CHEMICALS AND PHARMACEUTICALS LTDLAMOTRIGINE USP

DMF 365312021

CF PHARMA LTDInactiveLAMOTRIGINE

DMF 181372005

GEDEON RICHTER LTDInactiveLAMOTRIGINE

DMF 183532005

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveLAMOTRIGINE USP

DMF 183562005

UNION QUIMICO FARMACEUTICA SA (UQUIFA)InactiveLAMOTRIGINE

DMF 184392005

APOTEX PHARMACHEM INDIA PVT LTDInactiveLAMOTRIGINE

DMF 201292007

CAMBREX PROFARMACO MILANO SRLInactiveLamotrigine

DMF 211052007

ALKEM LABORATORIES LTDInactiveLAMOTRIGINE

DMF 213902008

SEQUEL PHARMACHEM PRIVATE LTDInactiveLAMOTRIGINE EP

DMF 226562009

WATERSTONE PHARMACEUTICALS HUBEI TIANMEN CO LTDInactiveLAMOTRIGINE

DMF 257752011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

3 letters from Drugs@FDA

Date	Submission	Document
Jul 21, 2026	SUPPL -1	View Letter (PDF)
Jul 21, 2026	SUPPL -2	View Letter (PDF)
Sep 18, 2025	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 10MG/ML

RLD

4 patents0 exclusivities▴

SUSPENSION;ORAL | Approved: Sep 16, 2025

Patents (4) · 9 use codes

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
11596634	May 29, 2040	—	—	—		—
11612566	May 29, 2040	—	—	—		—
12629377	May 29, 2040	—	—	Yes		—
12636289	May 29, 2040	—	—	Yes	—	—